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ISSNObjective: Plasma kynurenine/tryptophan ratio, a biomarker of indoleamine 2,3-dioxy-
genase-1 (IDO) activity, is a strong independent predictor of mortality in HIV-infected
Ugandans initiating antiretroviral therapy (ART) and may play a key role in HIV
pathogenesis. We performed a genome-wide study to identify potential host genetic
determinants of kynurenine/tryptophan ratio in HIV-infected ART-suppressed Ugandans.
Design/methods: We performed genome-wide and exome array genotyping and
measured plasma kynurenine/tryptophan ratio during the initial 6–12 months of
suppressive ART in Ugandans. We evaluated more than 16 million single nucleotide
polymorphisms in association with log10 kynurenine/tryptophan ratio using linear
mixed models adjusted for cohort, sex, pregnancy, and ancestry.
Results: Among 597 Ugandans, 62% were woman, median age was 35, median
baseline CD4þ cell count was 135 cells/ml, and median baseline HIV-1 RNA was
5.1 log10 copies/ml. Several polymorphisms in candidate genes TNF, IFNGR1, and
TLR4 were associated with log10 kynurenine/tryptophan ratio (P<5.0105). An
intergenic polymorphism between CSPG5 and ELP6 was genome-wide significant,
whereas several others exhibited suggestive associations (P<5.0107), including
genes encoding protein tyrosine phosphatases (PTPRM and PTPRN2) and the vitamin D
metabolism gene, CYP24A1. Several of these single nucleotide polymorphisms were
associated with markers of inflammation, coagulation, and monocyte activation, but
did not replicate in a small US cohort (N¼262; 33% African-American).
Conclusion: Our findings highlight a potentially important role of IFN-g, TNF-a, and
Toll-like receptor signaling in determining IDO activity and subsequent mortality risk in
HIV-infected ART-suppressed Ugandans. These results also identify potential novel
pathways involved in IDO immunoregulation. Further studies are needed to confirm
these findings in treated HIV-infected populations.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:1807–1815Keywords: antiretroviral therapy, genome-wide association study, HIV,
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1808 AIDS 2016, Vol 30 No 11Introduction Ugandan cohort, kynurenine/tryptophan ratio was theDespite effective antiretroviral therapy (ART), HIV-
infected individuals experience higher rates of mortality
and aging-associated diseases than HIV-uninfected con-
trols [1,2]. Markers of immune activation predict clinical
progression of disease, but even with ART suppression,
immune activation levels fail to normalize [3,4]. To date,
the specific biologic pathways driving persistent immune
activation and its relationship to mortality remain unclear.
One proposed mechanism is the indoleamine 2,3-
dioxygenase (IDO)-induced tryptophan catabolism path-
way, which can be quantified as the ratio of kynurenine to
tryptophan in plasma. IDO plays a critical role in
autoimmune disorders [5], cancer [5], and fetal tolerance
during pregnancy [5]. IDO is a key immunoregulatory
enzyme that converts tryptophan to kynurenine [6].
Bacterial molecules such as lipopolysaccharide (LPS) and
proinflammatory cytokines such as IFN-g, TNF-a, and
TGF-b promote increased IDO activity (Fig. 1) [7,8].
Several IDO-induced catabolites have been shown to
decrease T-cell proliferation and function [9], and may
compromisemucosal integrity, thereby increasing bacterial
translocation and systemic immune activation [10]. These
downstream effects may contribute to increased morbidity
and mortality even during ART suppression [11].
Asymptomatic untreated HIV-infected participants have
higher kynurenine/tryptophan ratios than HIV-unin-
fected controls, whereas HIV-infected participants with
progression to AIDS have the highest kynurenine/
tryptophan ratios [12]. Though IDO activity declines
with ART, IDO has also been associated with a significant
increase in mortality risk in Ugandans, both during
untreated and treated HIV disease [11]. In a subsequent
analysis of multiple immune markers in this same Copyright © 2016 Wolters Kluwer H
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Fig. 1. Schematic illustrating the potential contribution of IDO to
and mortality during treated HIV infection. 3-HAA, 3-hydroxya
dioxygenase; i-FABP, intestinal fatty acid binding protein; IFN
tryptophan; LPS, lipopolysaccharide; MF, macrophage; sCD14, so
necrosis factor receptor; TGF-b, transforming growth factor beta;strongest independent risk factor for mortality, even after
adjusting for other markers of inflammation (IL-6),
monocyte activation (sCD14), and CD4þ or CD8þ
T-cell activation (%CD38þHLA-DRþ) [13]. Kynure-
nine/tryptophan ratio has also been shown to predict
mortality in ART-suppressed North Americans [3,4].
We performed a genome-wide association study (GWAS)
of kynurenine/tryptophan ratio in HIV-infected Ugan-
dans initiating ART. The goal of the study was to identify
potential targets for intervention – perhaps in genes other
than IDO itself – that may naturally (and presumably
safely) influence IDO immunoregulation. We performed
both a candidate gene (based on known factors that
influence the IDO pathway) and genome-wide analysis.
We found that single nucleotide polymorphisms (SNPs)
in TNF, IFNGR1, and TLR4 and SNPs in two additional
pathways – one involving protein tyrosine phosphatase
signaling and another related to vitamin D metabolism –
are strongly associated with IDO activity. Several of
the SNPs identified from these analyses were also
associated with markers of monocyte activation
(sCD14 and sCD163) and inflammation (IL-6 and D-
dimer), additional biomarkers previously associated with
increased risk of mortality during treated HIV disease.
These findings provide further support that variation at
these loci may play an important role in influencing the
IDO pathway, as well as other interrelated immunologic
pathways.Materials and methods
Study participants
Participants were sampled from the Uganda AIDS rural
treatment outcomes (UARTO) and anti-retrovirals forealth, Inc. All rights reserved.
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Genetics of KT ratio during treated HIV Lee et al. 1809Kaposi’s sarcoma (ARKS) cohorts in Uganda. UARTO
includes HIV-infected individuals initiating first ARTat a
rural clinic in Mbarara. ARKS includes HIV-infected
participants with mild-to-moderate cutaneous Kaposi’s
sarcoma at a specialty clinic in Kampala. The primary
ART regimen included two nucleoside reverse tran-
scriptases (e.g. zidovudine/lamivudine, stavudine/lami-
vudine, or tenofovir/emtricitabine) and a nonnucleoside
reverse transcriptase (e.g. nevirapine or efavirenz).
Participants were included if they had sustained plasma
HIV RNA less than 400 copies/ml [the lower limit of
detection of an earlier Amplicor assay (Roche); the same
cutoff was applied to a more recent Cobas Taqman assay
(Roche) to maintain consistency], kynurenine/trypto-
phan ratio at month 6 and/or 12 of ART, and genotype
data. ARKS participants were excluded for active
untreated opportunistic infections or mucocutaneous
Kaposi’s sarcoma requiring chemotherapy. All partici-
pants provided written informed consent. This research
was approved by the institutional review boards at each
site and the University of California, San Francisco.
Phenotype and covariate data
Demographic and clinical data were collected at screening
and follow-up visits approximately every 3 months. Data
included self-reported pregnancy status and symptom
reporting, as well as fasting morning laboratory measures
(e.g., plasma HIV-1 RNA, CD4þ T-cell counts, and
archival of peripheral blood mononuclear cells), as
described previously [11]. Plasma kynurenine/trypto-
phan ratio was measured in cryopreserved plasma using
liquid chromatography–mass spectrometry/mass
spectrometry [14] at pre-ART and approximately 6 and
12 months of ART.Mortality and follow-up were tracked
via a limited vital status ascertainment program as
described previously [15]. Cause of death was classified
only in broad categories (e.g. illness, trauma, suicide, or
related to childbirth). For this study, deaths due to trauma,
injury, or suicide were excluded. Self-reported diagnoses
of tuberculosis (TB) and/or TB medication history were
adjudicated by reviewing clinical records and laboratory
smear/culture results [16]. These data were only available
for UARTO as TB diagnosis was an exclusion criterion
for the ARKS study [16].
Genotyping and quality control
Genome-wide genotyping was performed at the RIKEN
Center for Genomic Medicine using the Human Omni
Express Bead Chip (Illumina, San Diego, California,
USA), including over 700 000 SNPs. Additional whole
exome genotyping of over 200 000 coding putative
functional SNPs was performed at the University of
California, San Francisco using the AxiomWhole Exome
Array Chip (Affymetrix, Santa Clara, California, USA). A
total of 928 participant samples were genotyped with the
exome array and of these, 642were also genotyped using a
genome-wide array (Supplementary Fig. 1, http://
links.lww.com/QAD/A918). After excluding samples Copyright © 2016 Wolters Kluwedue to ineligibility (lack of viral suppression), inadequate
genotyping quality (<95% call rate), genetic relatedness
(IBD> 0.125), and heterozygosity (2 SD), 788 samples
passed quality control for exome and/or genome-wide
array data. Among these 788 samples with quality-
controlled genetic data, 597 also had existing kynur-
enine/tryptophan ratio data (at month 6 and/or 12 of
ART). We generated principal components using
Eigensoft to include as covariates for ancestry in linear
mixed effects models (http://genetics.med.harvard.edu/
reich/Reich_Lab/Software.html) [17].
Genome-wide single nucleotide polymorphism
imputation
Quality-controlled genotyping data were used to impute
additional genotypes using IMPUTE2 (http://mathgen.
stats.ox.ac.uk/impute/impute_v2.html). We performed
prephasing to estimate haplotypes prior to imputation,
using SHAPEIT (https://mathgen.stats.ox.ac.uk/genet-
ics_software/shapeit/shapeit.html). Only imputed SNPs
with imputation quality score at least 0.80 were included
in the final dataset.
Association analyses
We fit linear mixed effects regression models to test for
associations between genotypes (coded as allele dosages)
and log10 kynurenine/tryptophan ratios during month
6 and 12 of ART suppression. We restricted all analyses to
ART-suppressed timepoints because SNPs associated
with plasma kynurenine/tryptophan ratio prior
to sustained ART suppression would mostly reflect
genetic predictors of HIV viral load setpoint or CD4þ
T-cell count in these chronically HIV-infected partici-
pants initiating therapy. We also did not include HIV
RNA levels or CD4þ T-cell counts as covariates in the
models as these factors could potentially be intermediates
or colliders in a causal pathway between host genetics and
plasma kynurenine/tryptophan ratio. Only SNPs with
minor allele frequencies (MAF) more than 1% were
included in the analyses. The final model included
covariates for sex, pregnancy, and cohort (to account for
Kaposi’s sarcoma diagnosis [16] and other unmeasured
cohort-specific differences), as well as the first 10 principal
components to control for population stratification.
We performed candidate gene analyses on 17 307 SNPs
in the following genes (including 100 kilobases flanking
regions): IDO1, IDO2, IFNG, IFNGR1, IFNGR2,
TNF, TNFRSF1A, TGFB1, TGFBR1, TGFBR2,
TGFBR3, IFNA1, IFNAR1, IFNB1, TLR4, TLR7,
TLR8, and TLR9. For the candidate gene analyses, we
used a Bonferroni-adjusted significance threshold of P less
than 5 105, based on the number of SNPs tested. For
the genome-wide analysis, we considered suggestive
(P< 5.0 107) as well as genome-wide significant
(P< 5.0 108) SNPs [18]. This is especially important
in light of our limited sample size and allows for further
investigation of potentially biologically relevant SNPs.r Health, Inc. All rights reserved.
1810 AIDS 2016, Vol 30 No 11SNPs exhibiting suggestive or significant associations
with kynurenine/tryptophan ratios were then tested for
association with additional biomarkers (e.g., IL-6,
D-dimer, and others) using linear mixed regression.
Replication analysis
We performed validation analyses among participants in
the AIDS Clinical Trials Group (ACTG) studies NWCS
279 and NWCS 329 who had both GWAS [19] and
kynurenine/tryptophan ratio data at 1 year of ART
suppression [4]. Linear regressions were adjusted for
ancestry, batch (for kynurenine/tryptophan ratio
measurements), case-control status (occurrence of non-
AIDS defining events) [4], and sex.Results
Among 597 participants, 43% in ARKS and 70% in
UARTO were woman, the median age was 35 years,
median baseline CD4þT-cell count was 135 cells/ml, and
median HIV RNAwas 5.1 log10 copies/ml. At month 12
of ART, the median CD4þ T-cell count was 266 cells/ml,
and all participants had HIV RNA 2.6 log10 copies/ml or
less (Table 1). Median kynurenine/tryptophan ratios in
UARTO and ARKS were similar (63 versus 66 (nmol/l)/
(mmol/l), P¼ 0.93). Variability (R2) in kynurenine/
tryptophan ratio at month 6 was 3.7% and at month 12
was 3.0%, and there was a statistically significant decline in
plasma kynurenine/tryptophan ratio from month 6 to 12
of ART (69–60 (nmol/l)/(mmol/l), P< 0.0001) overall,
as well as within individuals (P< 0.0001), consistent with
previously published data [11].
By principal components analyses using 1000 Genomes
reference data, our Ugandan population was most
genetically related to Luhyans in Kenya (Supplementary
Fig. 2, http://links.lww.com/QAD/A918). Q–Q plots
of the discovery genome-wide association results gave an
inflation factor of l¼ 1.04, indicating that the results are
not confounded by genetic ancestry (Supplementary
Fig. 3, http://links.lww.com/QAD/A918). Copyright © 2016 Wolters Kluwer H
Table 1. Characteristics of HIV-infected individuals initiating first antiretro
AIDS rural treatment outcomes cohorts.
Characteristics
Age
Female
Baseline CD4þ cell count (cells/ml)
Proximal CD4þ cell count (cells/ml)b
Baseline HIV RNA (log10 copies/ml)
Proximal HIV RNA (log10 copies/ml)
Plasma kynurenine/tryptophan ratio (nmol/l)/mmol/l)c
ARKS, anti-retrovirals for Kaposi’s sarcoma; ART, antiretroviral therapy; U
aMedian and interquartile range shown except for sex (number and perce
b‘‘Proximal’’ refers to the most recent CD4þ T-cell count or HIV RNA rela
cPlasma kynurenine/tryptophan ratio during months 6–12 of ART.Candidate gene single nucleotide polymorphisms
and plasma kynurenine/tryptophan ratio
Several SNPs in the candidate genes TNF, IFNGR1, and
TLR4 were associated with kynurenine/tryptophan ratio
at the Bonferroni-adjusted significance level of P less than
5.0 105, conferring between a 1.11 and 1.71-fold
increase in kynurenine/tryptophan ratio per increase in
minor allele copy (Table 2). These included SNPs in the
50 and 30 regions of TNF, a SNP in IFNGR1, and a SNP
in TLR4. SNPs strongly associated with kynurenine/
tryptophan ratio included rs17200810 (30 ofTNF), which
localizes to a region predicted to bind to several
transcription factors, and rs276565 (50 of IFNGR1)
and rs270148 (intron 2 of TLR4), which are in active
H3K27Ac histone mark regulatory regions (Supple-
mentary Fig. 4, http://links.lww.com/QAD/A918). The
SNP in the IFNGR1 region also lies 100 kb upstream of
IL20RA and 43 kb downstream of IL22RA2.
Genome-wide single nucleotide polymorphisms
and plasma kynurenine/tryptophan ratio
Suggestive and significant SNPs from the genome-wide
analysis were estimated to increase kynurenine/trypto-
phan ratio by 1.20–1.61-fold per increase in minor allele
copy (Table 3). An intergenic SNP (rs56185965, 50 of
CSPG5 and 30 of ELP6) was significantly associated with
kynurenine/tryptophan ratio at the genome-wide level
(P< 5.0 108), whereas several SNPs exhibited sug-
gestive associations (Fig. 2). Among the latter, two SNPs
(rs6950107 and rs75257475) were in genes encoding two
distinct protein tyrosine phosphatases; these SNPs localize
to predicted transcription factor-binding sites for proteins
involved in activator protein 1 signaling. A third SNP
(rs13041834) was 67 kb upstream of CYP24A1, a gene
encoding a key enzyme involved in vitamin
D metabolism, and lies in an H3K27Ac histone mark-
enriched region (Table 3, Supplementary Fig. 5, http://
links.lww.com/QAD/A918). This SNP also lies 16 kb
downstream of BCAS1 (Breast Carcinoma Amplified
Sequence 1), a gene that is overexpressed in breast cancer
cell lines [20], and 18 kb downstream ofMIR4756, a small
noncoding RNA gene or microRNA, of unknown
clinical significance [21].ealth, Inc. All rights reserved.
viral therapy in the anti-retrovirals for Kaposi’s sarcoma and Uganda
ARKSa (N¼177) UARTO (N¼420)
39 (29–40) 35 (29–40)
76 (43%) 292 (70%)
116 (25–250) 137 (80–206)
273 (171–465) 257 (175–257)
5.2 (4.9–5.5) 5.1 (4.1–5.5)
2.6 2.6
63 (50–93) 66 (50–86)
ARTO, Uganda AIDS rural treatment outcomes cohort.
ntage).
tive to the most recent kynurenine/tryptophan ratio measurement.
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Table 2. Association of candidate gene polymorphisms with kynurenine/tryptophan ratioa.
SNPb Exp (beta)c 95% CI P Location MAF Gene
rs17200810d 1.65 (1.35, 2.02) 1.41106 30 0.02 TNF
rs34451538 1.50 (1.26, 1.79) 3.90106 50 0.03 TNF
rs276565e 1.11 (1.06, 1.16) 5.30106 50 0.28 IFNGR1f
rs114064880 1.71 (1.36, 2.16) 5.33106 50 0.01 TNF
rs11575838 1.68 (1.34, 2.11) 7.13106 30 0.01 TNF
rs2770148g 1.15 (1.08, 1.23) 2.94105 Intron 2 0.12 TLR4
CI, confidence interval; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
aLinear mixed effects regression models of log10 plasma kynurenine/tryptophan ratio were adjusted for sex, pregnancy, cohort (ARKS versus
UARTO), and the first ten principal components.
bGenotyped or imputed SNP.
cFold change in kynurenine/tryptophan ratio (nmol/l)/mmol/l) per copy of minor allele.
dGenotyped SNP, multiple transcription factors predicted to bind to this loci (e.g., IRF4, JUND; RUNX).
eGenotyped SNP, in active H3K27Ac mark regulatory region.
fThis SNP also lies 100 kb upstream of IL20RA and 43 kb downstream of IL22RA2.
gIn linkage disequilibrium with genotyped SNP, rs1413088.Associations between selected single nucleotide
polymorphisms and markers of inflammation and
immune activation
To evaluate whether SNPs associated with kynurenine/
tryptophan ratio might be related to additional immu-
nologic pathways that have been associated with increased
morbidity/mortality during treated HIV disease [4,11],
we evaluated SNPs in relation to D-dimer, IL-6, sCD163,
sCD14, and CD4þ and CD8þ T-cell activation levels
during ART suppression (Supplementary Table 1, http://
links.lww.com/QAD/A918). These biomarkers were
only modestly correlated with each other (R¼ 0.09–
0.45), with the exception of CD4þ and CD8þ T-cell
activation (R¼ 0.67) (Supplementary Fig. 6, http://
links.lww.com/QAD/A918). Several of the SNPs ident-
ified in the candidate gene analysis were associated with
increased monocyte activation (sCD163 and sCD14) and
increased IL-6 (Supplementary Table 1, http://
links.lww.com/QAD/A918). SNPs identified in the
genome-wide analysis were associated with sCD163,
sCD14, D-dimer, and IL-6 (Supplementary Table 2,
http://links.lww.com/QAD/A918). Copyright © 2016 Wolters Kluwe
Table 3. Association of polymorphisms with plasma kynurenine/tryptoph
SNPb Exp (beta)c 95% CI P
rs56185965 1.55 (1.33, 1.79) 8.73109
rs6950107d 1.44 (1.26, 1.64) 7.14108
rs17085469 1.20 (1.13, 1.29) 7.75108
rs13041834e 1.17 (1.10, 1.25) 3.13107
rs75257475f 1.23 (1.13, 1.32) 2.95107
rs200564710 1.30 (1.18, 1.44) 3.20107
rs114598920 1.37 (1.21, 1.54) 3.73107
rs115718192 1.61 (1.34, 1.93) 4.13107
rs76101033 1.41 (1.23, 1.61) 4.29107
CI, confidence interval; MAF, minor allele frequency; SNP, single nucleot
aLinear mixed effects regression models of log10 plasma kynurenine/trypt
UARTO), and the first ten principal components.
bGenotyped or imputed SNP.
cFold change in kynurenine/tryptophan ratio (nM/mM) per copy of minor a
dSNP predicted to decrease binding to SMAD3.
eSNP in active H3K27Ac mark region, in linkage disequilibrium with geno
fSNP predicted to alter binding to FOSL2, in linkage disequilibrium with
rs1695225.Associations between selected single nucleotide
polymorphisms and mortality
There were too few deaths in the cohort (35 deaths over a
median of 7 years of follow-up) to directly perform a
genome-wide analysis of predictors of mortality [11].
Nonetheless, we were able to assess whether SNPs
associated with kynurenine/tryptophan ratio were also
associated with mortality. We observed statistically
significant associations with mortality and rs13041834
[adjusted hazard ratio¼ 1.82, 95% confidence interval
(CI)¼ 1.06, 3.13] and rs75257475 (adjusted hazard
ratio¼ 2.05, 95% CI¼ 1.12, 3.76) (Supplemental Table
3, http://links.lww.com/QAD/A918, Supplementary
Fig. 7, http://links.lww.com/QAD/A918).
Sensitivity analyses to evaluate potential effect of
nongenetic factors during early antiretroviral
therapy
We had limited data on nongenetic factors, such as
coinfections. However, we were able to perform posthoc
analyses excluding 39 individuals with adjudicated TB
diagnoses and found no significant change in the effectr Health, Inc. All rights reserved.
an ratio from genome-wide analysisa.
Location MAF Nearest gene(s)
Intergenic 0.02 CSPG5; ELP6
Intron 6 0.03 PTPRN2
50 0.10 RP11–736G13.1
Intergenic 0.12 CYP24A1; BCAS1; MIR4756
Intron 1 0.07 PTPRM
Intergenic 0.05 HOMER1; PAPD4
Intron 1 0.03 CLSTN2
Intergenic 0.02 TFRC; SDHAP1
Intron 2 0.02 RP11–6757F12.1
ide polymorphism.
ophan ratio were adjusted for sex, pregnancy, cohort (ARKS versus
llele.
typed SNP, rs6064045.
11 other SNPs with P less than 1107, including genotyped SNP
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Fig. 2. Manhattan plot for association analyses. Genome-wide association test results are shown as-log10transformed P values for
the linear mixed effects regression analyses of plasma log10 kynurenine/tryptophan ratio. Chromosomal location of single
nucleotide polymorphisms is indicated on the x-axis. Single nucleotide polymorphisms significantly (P<5.0108) or sugges-
tively (P<5.0105) associated with plasma log10 kynurenine/tryptophan ratio are noted above the red or blue line, respectively.estimates – though exclusion of these participants
reduced the sample size and significance of some
associations (Supplementary Table 4, http://links.lww.-
com/QAD/A918). We also compared the associations
between SNPs and kynurenine/tryptophan ratios at
months 6 and 12 of ART separately to evaluate potential
nongenetic influences (i.e. inflammatory conditions) that
might increase kynurenine/tryptophan ratio during early,
but not later, ART timepoints. Of the 597 participants,
586 had kynurenine/tryptophan ratio measurements at
month 6 and 538 had kynurenine/tryptophan ratio
measurements at month 12 of ART. The effect estimates
were largely unchanged at month 12 compared with
month 6 of ART (Supplementary Table 5, http://links.
lww.com/QAD/A918).
Attempt to replicate findings in a non-African
sample of convenience
We lacked resources to be able to measure kynurenine/
tryptophan ratio in an additional African cohort.
However, we had access to existing data from ACTG
studies that included participants with genome-wide
array [19] and kynurenine/tryptophan ratio data (at 1 year
of ART suppression) [4] (Supplemental Table 6, http://
links.lww.com/QAD/A918). Although this ACTG
cohort was smaller than our Ugandan sample (262 versus
597 participants), only assessed kynurenine/tryptophan
ratio at a single timepoint (as opposed to two timepoints
in our Ugandan study), and had 33% participants with
African ancestry (Supplementary Table 6, http://
links.lww.com/QAD/A918), we evaluated whether the Copyright © 2016 Wolters Kluwer HSNPs associated with kynurenine/tryptophan ratio in our
Ugandan cohort might be replicated – but were unable to
confirm these findings (Supplementary Tables 7 and 8,
http://links.lww.com/QAD/A918).Discussion
We performed a genome-wide study to identify potential
host genetic determinants of kynurenine/tryptophan
ratio in HIV-infected ART-suppressed Ugandans. A
previous study in SIV-infected rhesus macaques of direct
IDO and CTLA-4 inhibition led to severe autoimmune
necrotizing pancreatitis in animals [22]. However, several
phase I and II cancer treatment trials of direct IDO
inhibition are currently underway [23]. The goal of the
present study was to identify pathways that may modify
IDO activity during treated HIV disease, potentially
identifying targets for interventions other than IDO itself.
The specific candidate genes assessed in the study were
selected by a priori knowledge of factors that modulate
IDO in published in-vitro or animal model studies. IDO
is upregulated in dendritic cells and phagocytes by
proinflammatory cytokines including IFN-a, IFN-g,
TNF-a, and TGF-b [8,24]. Translocation of microbial
products, including LPS, may stimulate Toll-like recep-
tors, which then induce IDO activity [25]. The relative
importance of these regulators in vivo during treated HIV
infection, however, remains unclear.ealth, Inc. All rights reserved.
Genetics of KT ratio during treated HIV Lee et al. 1813We found that SNPs in TNF, IFNGR1, and TLR4 were
strongly associated with kynurenine/tryptophan ratio.
Several of these SNPs localize to potential functionally
relevant regions – for example, rs17200810 (TNF) lies in
a region predicted to bind to several transcription factors
involved in host immunoregulation, including the
response to HIV (e.g. RELA [26], IRF4 [27], and
JUND [28]). Both rs276565 (IFNGR1) and rs270148
(TLR4) lie in active H3K27Ac histone mark regulatory
regions, loci that exhibit increased enhancer activity [29].
Interestingly, rs276565 (IFNGR1) also lies near IL20RA,
which encodes for the IL-20 receptor (IL-20RA) and
IL22RA2, which encodes for the soluble form of the
IL-22 receptor (IL-22BP) (Supplementary Fig. 4B,
http://links.lww.com/QAD/A918). Both IL-20 and
IL-22 are members of the IL-20 subfamily of cytokines,
which plays a critical role in enhancing the host innate
immune response such as during viral infection or with
intestinal epithelial homeostasis [30].
In the genome-wide analysis, we identified additional
pathways that might plausibly be involved in IDO
immunoregulation. PTPRN2 and PTPRM are both
protein tyrosine phosphatases (PTPs), which, with
protein tyrosine kinases, rapidly modulate signaling
processes to maintain cell proliferation, differentiation,
and gene transcription [31,32]. Based on ENCODE data,
rs6950107 (PTPRN2) is predicted to decrease binding to
SMAD3 [33], and rs75257475 (PTPRM) lies in a region
that binds FOLS2 [34], a transcription factor that interacts
with SMAD3 [35]. SMAD3 is a key intracellular effector
of TGF-b signaling [36], and via formation of the
activator protein 1 transcription factor complex [37] and
binding to Foxp3 [38], plays a critical role in the
development, function, and survival of regulatory T cells.
A second potential pathway identified from the genome-
wide analysis is the vitamin D pathway. CYP24A1
(rs13041834) encodes the key enzyme catalyzing the
metabolism of active vitamin D. In mouse models,
vitamin D inhibits T-cell proliferation [39], suppresses
Th17 production [40], and induces regulatory T-cell
expansion [41,42] – immunologic effects strikingly
similar to those of IDO. Mice administered vitamin D
also generates tolerogenic mature dendritic cells with
enhanced TGFB and IDO mRNA expression, and
increased IL-10 production with regulatory T-cell
expansion [43]. In HIV-infected ART-suppressed
patients, vitamin D supplementation is associated with
decreased T-cell activation [44]. Of note, this SNP also
lies downstream of BCAS1 andMIR4756. However, the
clinical significance of these genes and their association
with IDO signaling are unknown.
We identified one genome-wide significant SNP, but to
our knowledge, neither chondroitin sulfate proteoglycan
a5 (CSPG5) nor elongator acetyltransferase complex
subunit (ELP6) is biologically relevant molecules in IDO Copyright © 2016 Wolters Kluwesignaling. The SNP does not lie in a putative regulatory
site, polymorphisms closer to these two genes were not
associated with kynurenine/tryptophan ratio, and this
SNP was not associated with other markers of immune
dysfunction.
Our data are in contrast to a recent GWAS, which did not
find any polymorphisms significantly associated with
markers of immune activation and microbial translocation
(sCD14 and i-FABP levels) [45]. However, only
untreated HIV-infected individuals were included in
the study, potentially making it more difficult to
overcome additional variation due to the extent of
disease progression and genetic and nongenetic
contributors to viral load setpoint (factors that might
confound the relationship between host genetics and
sCD14). Participants were also restricted to those with
higher CD4þT-cell counts, possibly excluding those with
the most microbial translocation. Our study minimizes
potential confounding by plasma HIV RNA levels by
only evaluating ART-suppressed individuals. By sampling
two different timepoints per participant, we also
minimize within-subject variability and increase our
power to detect an association with host genetic factors.
Our study has several limitations that deserve mention.
First, we had limited data on nongenetic factors, such as
coinfections. We were able to adjudicate potential TB
diagnoses [16] and found little change in effect estimates
after excluding these individuals. We also performed
posthoc analyses of SNPs in relation to months 6 and
12 kynurenine/tryptophan ratios separately. These
analyses did not demonstrate any bias toward a stronger
relationship at month 6, which might suggest potential
confounding by coinfection or other inflammatory
conditions. Second, we had too few deaths in this cohort
to directly perform a genome-wide analysis of mortality.
Due to the lack of a dedicated mortality tracking system
in Uganda, we also did not have information on the
exact cause of death, for example, AIDS-related death.
However, we did identify two SNPs that were
significantly associated with mortality, suggesting that
the genetic determinants of this pathway may be clinically
meaningful. Third, though we included nearly 600
participants, based on a median of two observations per
participant, we only had 80% power to detect SNPs that
explain approximately 5% of the variance in plasma log10
kynurenine/tryptophan ratio (assuming a log-additive
model, two-tailed Type I error rate of 5.0 108 and
MAF 1%). This difference would be equivalent to a
2.0-fold difference in kynurenine/tryptophan ratio,
corresponding to an estimated 3.7-fold increase in
mortality risk [11]. Thus, it is likely that we lacked
sufficient power, particularly for less common SNPs, to
detect effect sizes that might be most clinically relevant.
Finally, we did not have the resources to be able to
measure kynurenine/tryptophan ratio in an African
replication cohort. We instead analyzed existing ACTGr Health, Inc. All rights reserved.
1814 AIDS 2016, Vol 30 No 11data but were unable to confirm the associations with
kynurenine/tryptophan ratio observed in our Ugandan
study. Based on the above estimates of power and the small
number of participants with African ancestry in the
replication cohort, however, we cannot definitively
exclude the associations observed in our Ugandan study
at this time.
In conclusion, we identified several polymorphisms
associated with kynurenine/tryptophan ratio during
treated HIV disease. Several of these SNPs lie in
biologically plausible regions that could modulate the
IDO pathway; these include polymorphisms in genes
related to proinflammatory cytokines such as IFN-g,
TNF-a, and TGF-b, as well as genes involved in Toll-like
receptor signaling and vitamin D metabolism. Although
the SNP associations identified herein are plausible, in a
small, primarily white cohort from a resource-rich
region, we were unable to confirm these findings. The
immunologic pathways predicting mortality among HIV-
infected Ugandans may be different than those described
in resource-rich settings; immune recovery (i.e. CD4þ
T-cell count) after ART initiation is significantly slower in
resource-limited compared with resource-rich regions
[15]. There may be nongenetic differences between
regions that could plausibly affect kynurenine/tryptophan
ratio such as viral clade (e.g. A and D in Uganda versus B
in the United States) and prevalent coinfections. Further
studies are needed to confirm the role of these SNPs in
IDO-mediated gut epithelial immunity, especially among
African populations.Acknowledgements
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